Mandatory Trial Reporting To Be Required For Nearly Half Of IND Protocols

Almost half of investigational new drug trial protocols submitted to FDA will be subject to mandatory reporting requirements for trials of drugs for serious or life-threatening diseases, the agency estimated in a March 29 notice of draft guidance availability